|
Basic Characteristics of Mutations
|
|
Mutation Site
|
T97A |
|
Mutation Site Sentence
|
Of 192 individuals, 1 (0.5%) showed resistance (a combination of T66I and T97A) against DTG. Eight (4.2%) patients harbored any DRM against 3TC. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
IN |
|
Standardized Encoding Gene
|
gag-pol:155348
|
|
Genotype/Subtype
|
HIV-1 |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
HIV Infections
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
dolutegravir(DTG) |
|
Location
|
Austria |
|
Literature Information
|
|
PMID
|
31915716
|
|
Title
|
Antiretroviral Treatment Simplification With 2-Drug Regimens: Impact of Transmitted Drug Resistance Mutations
|
|
Author
|
Kessler HH,Stelzl E,Blazic A,Mehta SR,Benezeder AS,Genger-Hackl C,Santner BI,Chaillon A,Hoenigl M
|
|
Journal
|
Open forum infectious diseases
|
|
Journal Info
|
2019 Dec 18;7(1):ofz535
|
|
Abstract
|
The frequency of clinically relevant transmitted drug resistance mutations (DRMs) against drugs used for 2-drug regimens was 15.6%, but only 2% were not eligible for 1 or more 2-drug regimens. More than 50% of patients harboring any clinically relevant DRMs were found to be part of genetic transmission clusters.
|
|
Sequence Data
|
-
|